Last reviewed 2026-05-31 · How we verify

Furmethide (FURTRETHONIUM)

Phase 2 active Small molecule ✓ Verified May 2026

Furmethide (generic name: FURTRETHONIUM) is a furtrethonium drug. It is currently in Phase 2 development.

Furmethide works by blocking the action of acetylcholine at the muscarinic acetylcholine receptor M2.

Furmethide is a small molecule with the synonyms FURAMON, FURMETHIDE IODIDE, FURTRETHONIUM IODIDE, IODURE DE FURTRETHONIUM, IODURO DE FURTRETONIO, and NSC-27126. Its modality is classified as a small molecule.

Likelihood of approval

12.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	FURTRETHONIUM
Drug class	furtrethonium
Target	Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	Phase 2

Mechanism of action

Think of acetylcholine as a key that unlocks a door in your body. The muscarinic acetylcholine receptor M2 is like a lock on that door. When furmethide blocks this lock, it prevents acetylcholine from doing its job, which can affect various bodily functions.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Furmethide CI brief — competitive landscape report
Furmethide updates RSS · CI watch RSS

Frequently asked questions about Furmethide

What is Furmethide?

Furmethide (FURTRETHONIUM) is a furtrethonium drug.

How does Furmethide work?

Furmethide works by blocking the action of acetylcholine at the muscarinic acetylcholine receptor M2.

What is the generic name of Furmethide?

FURTRETHONIUM is the generic (nonproprietary) name of Furmethide.

What drug class is Furmethide in?

Furmethide belongs to the furtrethonium class. See all furtrethonium drugs at /class/furtrethonium.

What development phase is Furmethide in?

Furmethide is in Phase 2.

What does Furmethide target?

Furmethide targets Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3 and is a furtrethonium.

Drug class: All furtrethonium drugs
Target: All drugs targeting Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3
Therapeutic area: All drugs in Neuroscience

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing